Fulvestrant plus targeted agents versus fulvestrant alone for treatment of hormone-receptor positive advanced breast cancer progressed on previous endocrine therapy: a meta-analysis of randomized controlled trials

Breast Cancer

Volumn 24, Issue 3, 2017, Pages 345-352

  Lin, Wen Zhao ^a   Xu, Qi Ni ^b   Wang, Hong Biao ^b   Li, Xu Yuan ^a  

^a SHANTOU CENTRAL HOSPITAL   (China)

^b CANCER HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Breast cancer; Fulvestrant; Meta analysis; Targeted therapy

Indexed keywords

AROMATASE INHIBITOR; BUPARLISIB; CD4 ANTIGEN; CD6 ANTIGEN; CEDIRANIB; FULVESTRANT; GANITUMAB; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3 KINASE; PICTILISIB; PLACEBO; SELUMETINIB; TAMOXIFEN; VANDETANIB; ANTINEOPLASTIC AGENT; ESTRADIOL; ESTROGEN RECEPTOR;

BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER HORMONE THERAPY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HORMONE RECEPTOR POSITIVE BREAST CANCER; HUMAN; META ANALYSIS; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; FEMALE; METABOLISM; MORTALITY; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTRADIOL; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 85015787765     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-017-0770-3     Document Type: Review

References (34)

1. Yang XR, Chang-Claude J, Goode EL, Couch FJ, Nevanlinna H, et al. Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst. 2011;103:250–63.
2. Sini V, Cinieri S, Conte P, De Laurentiis M, Leo AD, et al. Endocrine therapy in post-menopausal women with metastatic breast cancer: from literature and guidelines to clinical practice. Crit Rev Oncol Hematol. 2016;100:57–68.
3. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thürlimann B, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer. 2001;92:2247–58.
4. Mouridsen H, Sun Y, Gershanovich M, Perez-Carrion R, Becquart D, et al. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability. Oncologist. 2004;9:489–96.
5. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664–70.
6. Cope S, Ouwens MJNM, Jansen JP, Schmid P. Progression-free survival with fulvestrant 500 mg and alternative endocrine therapies as second-line treatment for advanced breast cancer: a network meta-analysis with parametric survival models. Value Health. 2013;16:403–17.
7. Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, et al. Results of the CONFIRM phase iii trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28:4594–600.
8. Johnston SRD, Kilburn LS, Ellis P, Dodwell D, Cameron D, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14:989–98.
9. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–9.
10. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
11. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.
12. Bergh J, Jonsson PE, Lidbrink EK, Trudeau M, Eiermann W, et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012;30:1919–25.
13. Howell A, Robertson JFR, Abram P, Lichinitser MR, Elledge R, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22:1605–13.
14. Johnston SRD, Kilburn LS, Ellis P, Dodwell D, Cameron D, et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14:989–98.
15. Leo AD, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2013;106:djt337.
16. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012;367:435–44.
17. Robertson JF, Dixon JM, Sibbering DM, Jahan A, Ellis IO, et al. A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer. Breast Cancer Res. 2013;15:R18.
18. Martin M, Loibl S, von Minckwitz G, Morales S, Martinez N, et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the Letrozole/Fulvestrant and Avastin (LEA) study. J Clin Oncol. 2015;33:1045–52.
19. Turner NC, Ro J, André F, Loi S, Verma S, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–19.
20. Baselga J, Im SA, Iwata H, Clemons M, Ito Y, et al. PIK3CA status in circulating tumor DNA predicts efficacy of buparlisib plus fulvestrant in postmenopausal women with endocrine-resistant HR+/HER2− advanced breast cancer: first results from the randomized, Phase III BELLE-2 trial. Program and abstracts of the San Antonio Breast Cancer Symposium (SABCS) S6-01. 2015
21. Hyams DM, Chan A, de Oliveira C, Snyder R, Vinholes J, et al. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study. Invest New Drugs. 2013;31:1345–54.
22. Robertson JFR, Ferrero J-M, Bourgeois H, Kennecke H, de Boer RH, et al. Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial. Lancet Oncol. 2013;14:228–35.
23. Clemons MJ, Cochrane B, Pond GR, Califaretti N, Chia SKL, et al. Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Res Treat. 2014;146:153–62.
24. Zaman K, Winterhalder R, Mamot C, Hasler-Strub U, Rochlitz C, et al. Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: a multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. Eur J Cancer. 2015;51:1212–20.
25. Krop IE, Mayer IA, Ganju V, Dickler M, Johnston S, et al. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2016;17:811–21.
26. Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, et al. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III Trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer—CALGB 40302 (alliance). J Clin Oncol. 2014;32:3959–66.
27. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im S-A, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.
28. Brodie A, Sabnis G. Adaptive changes result in activation of alternate signaling pathways and acquisition of resistance to aromatase inhibitors. Clin Cancer Res. 2011;17:4208–13.
29. Arpino G, Green SJ, Allred DC, Lew D, Martino S, et al. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res. 2004;10:5670–6.
30. Lauring J, Park BH, Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. J Natl Compr Canc Netw. 2013;11:670–8.
31. Nichols M. New directions for drug-resistant breast cancer: the CDK4/6 inhibitors. Future Med Chem. 2015;7:1473–81.
32. Miller TW, Hennessy BT, González-Angulo AM, Fox EM, Mills GB, et al. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. Clin Invest. 2010;120:2406–13.
33. Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nature Commun. 2016;7:11579.
34. Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2015;21:4760–6.